BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24893914)

  • 1. Potential therapeutic strategies for non - muscle invasive bladder cancer based on association of intravesical immunotherapy with p - mapa and systemic administration of cisplatin and doxorubicin.
    Dias QC; Nunes ID; Garcia PV; Favaro WJ
    Int Braz J Urol; 2016; 42(5):942-954. PubMed ID: 24893914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of intravesical instillation of a novel biological response modifier (P-MAPA) on progress of non-muscle invasive bladder cancer treatment in a rat model.
    Fávaro WJ; Socca EAR; Böckelmann PK; Reis IB; Garcia PV; Durán N
    Med Oncol; 2022 Jan; 39(2):24. PubMed ID: 34982270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer.
    Garcia PV; Apolinário LM; Böckelmann PK; da Silva Nunes I; Duran N; Fávaro WJ
    Int J Clin Exp Pathol; 2015; 8(5):4427-43. PubMed ID: 26191134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.
    Garcia PV; Seiva FR; Carniato AP; de Mello Júnior W; Duran N; Macedo AM; de Oliveira AG; Romih R; Nunes Ida S; Nunes Oda S; Fávaro WJ
    BMC Cancer; 2016 Jul; 16():422. PubMed ID: 27389279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
    Huang B; Huang G; Li W; Chen L; Mao X; Chen J
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
    de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
    J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model.
    Steinberg GD; Brendler CB; Squire RA; Isaacs JT
    J Urol; 1991 Mar; 145(3):647-53. PubMed ID: 1997724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
    Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
    Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC].
    Loriot Y; Rouprêt M
    Bull Cancer; 2020 Jun; 107(5S):S49-S55. PubMed ID: 32620207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
    Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
    Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical therapy for bladder cancer.
    Patel SG; Cohen A; Weiner AB; Steinberg GD
    Expert Opin Pharmacother; 2015 Apr; 16(6):889-901. PubMed ID: 25773220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valrubicin in refractory non-muscle invasive bladder cancer.
    Sharma P; Zargar-Shoshtari K; Sexton WJ
    Expert Rev Anticancer Ther; 2015; 15(12):1379-87. PubMed ID: 26569509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer.
    Hilton WM; Ercole B; Parekh DJ; Sonpavde G; Ghosh R; Svatek RS
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):949-57. PubMed ID: 21707292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and management of superficial bladder cancer.
    Amling CL
    Curr Probl Cancer; 2001; 25(4):219-78. PubMed ID: 11514784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment.
    Passos GR; Camargo JA; Ferrari KL; Saad MJA; de Mattos AC; Reis LO
    Med Oncol; 2017 Dec; 35(1):3. PubMed ID: 29209984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.